Last I heard was that the CSM was going to oversee the Chapter 11 filing. He has also received funding approval to hire you and rearview as expert advisers.
Multi Dose pens(you use the pen for multiple doses) but once it's empty then it goes in the bin. At least thats how I understand it. I think they have a patent for one with 30 injections(maybe less) it had like a dial. Inject turn one click inject again and so on. Multi use refers to different application li reconstitution/multidose etc.
Teva might have picked csync because they needed a reusable injector.
Ainto said that the pens are reusable I was under the impression the where not(so I deleted my original post but I went back and had another look and I get the impression that the pens are indeed disposable.
They are Multi Dose but......
I deleted my original post but check this out
"The Company's technology platforms include VIBEX® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva Pharmaceutical Industries, Ltd. that includes VIBEX® epinephrine, exenatide multi-dose pen, and another undisclosed multi-dose pen. Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring Pharmaceuticals BV. "
I thought I'll translate one of the articles before going to bed, so here it is :
eva launches new autoinjector Copaxone to improve adherence
The CSYNC has a more precise injection depth regulator
Monday, February 9, 2015, at 12:46
Teva Neuroscience presents its new csync autoinjector for patients with relapsing-remitting multiple sclerosis (RRMS) treated with glatiramer acetate (Copaxone). An innovative device which, thanks to its ease of use, help correct drug administration and improve the adhesion of these patients.
Carlos Teixeira, CEO of Teva in Spain.
"We developed the new autoinjector csync from information gathered from patients and nurses regarding improvements on their current device. This renovated device works differently than other injectors mode and being very easy to use, improves and facilitates the administration of COPAXONE "said Rainel Sánchez de la Rosa, medical director of Teva.
The csync autoinjector has a depth regulator more precise injection, which allows adjustment of 1mm to regulate the introduction of the needle, and a depth gauge injection easy to see.
Also has a beeper that warns the start and end of injection of the dose and confirms its complete administration, which -unido the indicator window that changes from white to red once it has been administered dose all offers greater confidence to patients.
Its new ergonomic design allows hold comfortably, has a simple button push injection and better location -located at the top of device-, and a red sash lock easily visible security. Some improvements for patients with MS who have difficulty moving your hands properly.
"It's funny to read this particular topic - couple of post from whogo, rearview, mbus, the rest is blank"
Interesting, since it must be impossible even for you to opine about something you have not read. This post must be to clear any confusion that Whogo, Rearview or Mbus have about the real world. I'm glad to see you are looking after them.
Andre posts this, crying about the Reddies he got....strange that he should worry about them.
"Some posted about First call rating, which is a junk information, computer generated from low ranking firms, to whom no body listen, it is fee, and is intended only to fool the small investors ?!?"
#From First call,
" 3 Analyst have given the stock of Antares Pharma, Inc. (NASDAQ:ATRS) a near short term price target of $5.5."
How do you compter generate an analyst? It's a good Idea but I'm not quite sure we are there yet.
Pay how many Billion to corner what is left after getting 50% to 80% of the market with an AB rated EPI?
Anyway it's an interesting subject, what happens to the AB rated EPI if Teva buys Mylan. Teva did not want to pursue Suma so it became an Antares product....think about it ATRS might become the owner of an AB rated EPI pen :o).......that should make the stock fly :o)
rearview you are the living proof that "on a message board a poster is entitled to post rubbish" as you say.
Why would Teva buy Mylan if they have an AB rated EPI around the corner, Take away EPI from Mylan what have you got left?
You obviously did not understan my question. It, was a fairly simple one.
"How many EPI Vibex do you expect ATRS to ship in 2015 and 2016?"
They are already shipping them now in "Launch quantities" to Teva, at least thats what they said on the CC but you may know better. Back to the original question:
How many EPI Vibex do you expect ATRS to ship in 2015 and 2016?
Aintno I have no problem If I erred on the low side :o), I posted thes before.
I guess large direct prchases outside of traditional channels might change the number of devices significantly.
"Mylan EPI Market in 2014 as posted was 1,600,000,000 Dollars,
The average price I found for buying 10 packs of two injectors was 430$ per Pack
So Using 435$ per pack Mylan shipped 1,600,000,000/215=approximately 7,500,000 Injectors.
It is now up to each person to figure out what kind of market share Teva will get and how much they will pay ATRS per injector and how much of that will be profit to ATRS.
Add a High single digit % Royalty with 100% going to bottom line.
And there you have it"
If you first became aware of this stock when it was above $5 you are one of the unlucky ones that probably bought at the top of the short squeeze caused by a warrant expiry event. That explains why you are such a bitter individual. Honestly someone as smart as you should not have gone into that trap......
The price of oil fell 10 percent this week, approaching its lowest price in six years. Many expect it to fall further in the coming weeks because supplies are rising and the summer driving season is still months away.
The lower crude prices will mean gasoline prices will slide lower in the coming weeks, and many drivers will likely pay under $2 a gallon in the summertime for the first time since 2004.
Oil prices had appeared to stabilize in a range nearly 15 percent higher than the depths they had reached in late January. But on Friday the International Energy Agency called a recent rise in oil prices a "head fake" and a "facade of stability."
"The rebalancing (of supply and demand) triggered by the price collapse has yet to run its course," the agency wrote in its monthly oil market report.
On Friday, oil fell $2.21, or 5 percent, to $44.84 a barrel, within 40 cents of its low for the year of $44.45. Here's what's behind the recent drop, and what else to look out for in the coming months.